开放期刊系统

MYH9 维持 CTNNB1 蛋白的稳定性并通过 Wnt/β-catenin通路促进胶质瘤的增殖、迁移与耐药

颜 欣, 周 海旭, 覃 德领, 谭 奔, 韦 选雷, 罗 起胜

摘要

目的 探究MYH9和CTNNB1的表达通过Wnt信号通路对脑胶质瘤细胞增殖、迁移和耐药的影响。方法 通过生物信息学分析MYH9和CTNNB1在脑胶质瘤中的表达及对脑胶质瘤患者的影响。利用蛋白免疫印迹(Western blot)检测MYH9和CTNNB1对Wnt信号通路的影响。利用免疫共沉淀技术(Co-IP)和免疫荧光共定位技术检测MYH9、CTNNB1、USP14之间的相互作用。利用放线菌酮(CHX)和蛋白酶抑制剂(MG132)检测MYH9和USP14对CTNNB1蛋白半衰期的影响。结论 MYH9与CTNNB1在脑胶质瘤中高表达,共同促进脑胶质瘤的恶性与耐药。

关键词

MYH9;胶质瘤;CTNNB1;USP14;去泛素化

全文:

PDF

参考

[1]Heese, O., et al., Complementary therapy use in patients with glioma: an observational study. Neurology, 2010. 75(24): p. 2229-35.

[2]Gerritsen, J., A. Vincent and S. De Vleeschouwer, Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome. Neuro Oncol, 2021. 23(3): p. 504-505.

[3]Ostrom, Q.T., et al., The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol, 2014. 16(7): p. 896-913.

[4]Jonsson, P., et al., Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clin Cancer Res, 2019. 25(18): p. 5537-5547.

[5]Turcan, S., et al., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012. 483(7390): p. 479-83.

[6]Kelley, M.J., et al., Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. Nat Genet, 2000.26(1): p. 106-8.

[7]Lv, Y., et al., Myosin IIA Regulated Tight Junction in Oxygen Glucose-Deprived Brain Endothelial Cells Via Activation of TLR4/PI3K/Akt/JNK1/2/14-3-3ε/NF-κB/MMP9 Signal Transduction Pathway. Cell Mol Neurobiol, 2019. 39(2): p. 301-319.

[8]Wu, Y., et al., Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling. Acta Pharm Sin B, 2022. 12(3): p. 1198-1212.

[9]Lin, X., et al., Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther, 2020. 5(1): p. 13.

[10]Gao, S., et al., TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3

β/β-catenin signalling. Nat Commun, 2022. 13(1): p. 2792. [11]Chen, M., et al., MYH9 is crucial for stem cell-like properties in non-small cell lung cancer by activating mTOR signaling. Cell Death Discov, 2021. 7(1): p. 282.

[12]Kas, S.M., et al., Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. Nat Genet, 2017. 49(8): p. 1219-1230.

[13]Ma, Y.S., et al., Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer, 2018. 17(1): p. 139.

[14]Nelson, W.J. and R. Nusse, Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 2004. 303(5663): p. 1483-7.

[15]Moon, R.T., et al., WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet, 2004. 5(9): p. 691-701.

[16]Que, T., et al., HMGA1 stimulates MYH9-dependent ubiquitination of GSK-3β via PI3K/Akt/c-Jun signaling to promote malignant progression and chemoresistance in gliomas. Cell Death Dis, 2021. 12(12): p. 1147.


(34 摘要 Views, 98 PDF Downloads)

Refbacks

  • 当前没有refback。